ConsumerGram: Patient Benefits from Biosimilar Competition

The recent approval of the first biosimilar drug by the FDA will mark the beginning of competition for a class of lifesaving medicines in the U.S., after nearly a decade of availability in Europe and elsewhere.  This ConsumerGram will explore how the pending introduction of competition for biologic drugs will lead to immense consumer benefits, both in terms of financial benefits and improved medical outcomes for patients.

Read or print the ConsumerGram

FacebooktwitterredditlinkedinFacebooktwitterredditlinkedin